Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Первичная и вторичная профилактика атеросклероза: как выбрать статин?
Первичная и вторичная профилактика атеросклероза: как выбрать статин?
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987; 257: 2176–80.
2. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet 364 (9438): 937–52.
3. Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin 2011; 27 (8): 1551–62.
4. Jones PH, Davidson MH, Stein EA et al. For the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152–60.
5. Nofer JR. Hyperlipidaemia and cardiovascular disease: HDL, inflammation and surprising results of AIM-HIGH study. Curr Opin Lipidol 2012; 23 (3): 260–2.
6. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy. J Am Coll Cardiol 2007; 49: 2231–7.
7. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81 (5): 582–7.
8. La Rosa J et al. for Treating to New Targets (TNT) Investigators. NEJM 2005; 352, www.nejm.org.
9. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292 (11): 1307–16.
10. Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Lancet 2010; 376 (9753): 1658–69.
11. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346 (7): 539–40.
12. Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol 2009; 104 (11): 1603–5.
13. Pepys MB, Hirschfield GM. C-reactive protein: a critical update.
J Clin Invest 2003; 111: 1805–12.
14. McPherson RA, Matthew R. Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 22nd ed. Elsevier Saunders: Philadelphia 2011; p. 254–5.
15. Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol 2009; 104 (11): 1603–5.
16. Hlatky MA. Expanding the Orbit of Primary Prevention – Moving beyond JUPITER. N Engl J Med 2008; 359: 2280–2.
17. O'Riordan M. FDA advisory panel votes in favor of broadened rosuvastatin indication 2009; http://www.theheart.org.
18. Sever PS, Dahlöf B, Poulter N, Wedel H et al. For the ASCOT Investigators. Lancet 2003; 361: 1149–58.
19. Colhoun HM, Betteridge DJ, Durrington PN et al. On behalf of the CARDS investigators*. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial. Lancet 2004; 364: 685–96.
2. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet 364 (9438): 937–52.
3. Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin 2011; 27 (8): 1551–62.
4. Jones PH, Davidson MH, Stein EA et al. For the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152–60.
5. Nofer JR. Hyperlipidaemia and cardiovascular disease: HDL, inflammation and surprising results of AIM-HIGH study. Curr Opin Lipidol 2012; 23 (3): 260–2.
6. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy. J Am Coll Cardiol 2007; 49: 2231–7.
7. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81 (5): 582–7.
8. La Rosa J et al. for Treating to New Targets (TNT) Investigators. NEJM 2005; 352, www.nejm.org.
9. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292 (11): 1307–16.
10. Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Lancet 2010; 376 (9753): 1658–69.
11. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346 (7): 539–40.
12. Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol 2009; 104 (11): 1603–5.
13. Pepys MB, Hirschfield GM. C-reactive protein: a critical update.
J Clin Invest 2003; 111: 1805–12.
14. McPherson RA, Matthew R. Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 22nd ed. Elsevier Saunders: Philadelphia 2011; p. 254–5.
15. Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol 2009; 104 (11): 1603–5.
16. Hlatky MA. Expanding the Orbit of Primary Prevention – Moving beyond JUPITER. N Engl J Med 2008; 359: 2280–2.
17. O'Riordan M. FDA advisory panel votes in favor of broadened rosuvastatin indication 2009; http://www.theheart.org.
18. Sever PS, Dahlöf B, Poulter N, Wedel H et al. For the ASCOT Investigators. Lancet 2003; 361: 1149–58.
19. Colhoun HM, Betteridge DJ, Durrington PN et al. On behalf of the CARDS investigators*. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial. Lancet 2004; 364: 685–96.
Авторы
Н.А.Ваулин
Городская клиническая больница №29 им. Н.Э.Баумана, Москва
Городская клиническая больница №29 им. Н.Э.Баумана, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.